Some good news out there. Really just waiting on Apple tomorrow.
Texas Instruments Beats Street, Gross Margin Sets Record
Chipotle shares soar on blockbuster earnings
Yep, 37 cents up is not bad for a "waiting around on Apple tomorrow" kind of day.
Especially on a red Nasdaq day.
Intel Corp. and the U.S. Department of Energy's Lawrence Berkeley National Lab (Berkeley Lab) have joined forces to develop what they describe as an innovative super-resist that addresses the demands of advanced nodes of 10nm and below using extreme-ultra-violet (EUV) light.
The problem was that EUV light sources are designed to flash as fast as a femtosecond, to prevent damage to the chip, but only very sensitive resists could work with such short exposure times. The kind of resists needed, cross-linked ones for their high-resolution and mechanical stability, unfortunately require longer exposure times. Thus the task of Intel and Berkeley labs was to create a super-resist that could create smooth high-resolution lines, but with high sensitivity for the quick EUV flashes.
"Resists today either emphasises cross linking for mechanical stability, but they have low sensitivity so are only used with e-beam lithography. When doing photolithography today they use amplified resists which have higher sensitivity to light," Paul Ashby, staff scientist at Berkeley Lab's Molecular Foundry, a DOE Office of Science user facility stated. "So our idea was to dilute cross-linking and add that to an amplified resist so we can have the advantages of both high sensitivity and mechanical stability."
The new type of resist is specifically targeted at EUV, which needs both sensitivity and mechanical stability, but the researchers are also hopeful that the new resist will improve edge-line roughness, which is increasingly important at the 10nm node and below.
"And it's not going to be 25. It appears high 32's is a good reloading point. What do the TA,Chart and Options experts think?"
[They say that the correction will start any second now. LOL
Or maybe that it already started and nobody got the memo.
Realistically ain't nothing gonna happen until Apple's results come out tomorrow. ]
"Not very much has ANYTHING to do with Mister Irrelevant any more. The American people and the rest of the world have him figured out...finally. It's just such a shame it took so long to learn what a vapid #$%$ he is."
[Well, it is difficult to compete with the staggering intellect of George Bush and his long list of achievements while in office.]
They've had it on order for over a year. They wait patiently at the door every day.
Seems like they would just hang out with the long crowd at their computers until they get the "out on the truck for delivery for today" message. But they don't. Another day of disappointment.
Still no correction.
Well, they can print out some more charts showing it will arrive tomorrow and wrap themselves in those.
Wow, we continue to see article after article these days on how ARM has closed the technology gap on Intel. In spite of the fact that ARM hasn't shipped a single FinFET processor EVER. Nor have we even seen any 20nm products shipping.
So, ARM's move to FinFET is a half-step, based on the 20nm node (which has had nothing but delays and still isn't shipping any finished product). Not even the 20nm node is done and we don't expect any volume shipments of it until 2015. Yet the media tells us that mass production of ARMs 14/16nm node will begin in 2015!!!
Not to mention that the development cycle for the 14/16nm node is over three years long!!!
Not to mention that moving a half-step to FinFET will not close the gap.
Not to mention that the 20nm and the 14/16nm nodes have bad economics and cost too much.
Not to mention that Intel will be in mass production of its 10nm node by the time ARM gets its half-step to FinFET done.
What kind of drugs do you have to take and how much before these predictions starts to sound reasonable?
The hype keeps moving up. It's now a screaming all day chorus in the media. But the bulls walked the market back up today. So, still no correction.
Really it's all about earnings. So, still just waiting on Apple tomorrow.
Another new fake ID started today:
2 posts | Last Activity: 14 minutes ago
Member since: Jul 21, 2014
Is this guy mental or what?
With Apple up tomorrow, Micron shorts are taking on huge risk by continuing to hang out in hopes of scraps.
"If Intel raises yearly dividend to $1.00 (from .90), we should see a huge rally."
[This post signifies Lucy moving from having all of his IDs on the basher side to having one of them on the positive side. So he can play both sides at the same time. Guess he's tired of having his head handed to him in a basket.]
But he keeps barking at his new daddy. What's up with that?
Lucy, you must be in love with the smack of the rolled-up newspaper on your rear end.
In the 2009-2012 period, the recent adverse events, mediocre reports and broad warnings would have tripped up the U.S. stock market. Now, with 2013’s steady rise under investors’ belts and 2014’s solid strength, the market is sending a clear message: Stock investing is back as investors focus on future fundamentals and return opportunities. Gone is the Great Recession-induced preoccupation with risk. It may be hard to remember from years past, but today’s stock market has the look of normality.
With normality now in control, its unfamiliarity has many investors and pundits still viewing the market through old lenses. This happy circumstance means we don’t need to worry about stocks being overvalued. There simply are too many underweighted stock investors (institutional and individual) out there that would love to buy on a dip. Such underlying, pent-up demand makes dips hard to come by, as shown by last week’s actions.
The U.S. stock market this week demonstrated resilience and strength in the face of adversity. Importantly, that condition is built on sound fundamentals, not over-optimism. The talk about over-valued stocks happens when an extended period of lower prices and periodic dips is followed by a run-up. To underweighted investors, it may seem that the now higher priced stocks must necessarily fall back to bargain prices again (thus allowing those underweighted investors to get back in at attractive prices). Eventually, though, that hope will peter out as prices continue to rise – exactly the condition in place this year.
Earnings season is now well under way for the second quarter. So far, things are looking good. The biotech sector has yet to see any significant earnings representation. That will change during the week of July 21 to July 25 when at least six large biotech outfits are scheduled to report second-quarter earnings and revenues.
24/7 Wall St. has prepared a brief sector calendar for its readers and given earnings previews as well. Consensus earnings per share (EPS), revenue estimates and price targets are from Thomson Reuters.
We have also added in color on each, as well as valuation and performance metrics. We would also note that earnings estimates, and even the expected earnings dates, can change prior to the reporting dates.
Lastly, we have had several biotech analysts come out favorably on the biotech sector ahead of earnings. That is in part from volatility of late, as well as a partial reaction to the commentary from Fed Chair Janet Yellen including biotech as having unnamed overvalued representation in the market.
These are the top six biotechs on deck to report in the week ahead.
From 24/7 Wall St.